A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH
LUSPATERCEPT IN PARTICIPANTS WITH TRANSFUSION DEPENDENT PRIMARY OR SECONDARY
MYELOFIBROSIS.
- Registry ID
- 220752
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Start date
- 2026-04-13
- Last update
- 2024-11-28
Conditions
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ADD-ON STUDY EVALUATING THE SAFETY AND EFFICACY OF NAVTEMADLIN PLUS RUXOLITINIB VS PLACEBO PLUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE A SUBOPTIMAL RESPONSE TO RUXOLITINIB
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE 3 CLINICAL
STUDY TO ASSESS EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B (P1101) IN ADULT
PATIENTS WITH PRE-FIBROTIC/EARLY PRIMARY MYELOFIBROSIS OR OVERT PRIMARY
MYELOFIBROSIS AT LOW OR INTERMEDIATE-1 RISK ACCORDING TO DIPSS PLUS (HOPEPMF): THE CORE STUDY AND ITS EXTENSION STUDY
- A PHASE 2 MULTICENTER STUDY OF TL-895 IN SUBJECTS WITH MYELOFIBROSIS, INDOLENT
SYSTEMIC MASTOCYTOSIS, MONOCLONAL MAST CELL ACTIVATION SYNDROME, OR NONMONOCLONAL MAST CELL ACTIVATION SYNDROME
- AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE
COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424)
STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT
(LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED
BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT
- A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR MONOTHERAPY IN SUBJECTS WITH JAK INHIBITOR-NAÏVE MYELOFIBROSIS AND MODERATE THROMBOCYTOPENIA
- A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
View on source registry